Highlights d T cell-induced IFN-g correlates the best to immune checkpoint blockade (ICB) therapy d Immune signatures increase in on-therapy patients regardless of response to therapy d ICB therapy decreases MYC and WNT signaling in patients with clinical response d IFN-g exposure of melanoma cells leads to a conserved transcriptome signature

No abstract

No abstract

No abstract

and has stock options in and is co-founder of Achilles Therapeutics. T.G.G. reports receiving an honorarium from Amgen, and having consulting and equity agreements with Trethera Corporation.